[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614890":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":65,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":44,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":44,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":93,"whyStopped":44,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Participants Receiving Low-Dose Naltrexone","EXPERIMENTAL",[12,13,14,15],"Drug: Low-Dose Naltrexone, 1.5mg","Drug: Low-Dose Naltrexone, 3.0mg","Drug: Low-Dose Naltrexone, 4.5mg","Drug: Low-Dose Naltrexone, 6.0mg",[17,24,28,32],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Low-Dose Naltrexone, 1.5mg","Low-Dose Naltrexone (LDN) is not a commercially available drug and will be compounded for this study. LDN will be taken orally, up to once per day.",[9],[23],"Naltrexone",{"type":18,"name":25,"description":20,"armGroupLabels":26,"otherNames":27},"Low-Dose Naltrexone, 3.0mg",[9],[23],{"type":18,"name":29,"description":20,"armGroupLabels":30,"otherNames":31},"Low-Dose Naltrexone, 4.5mg",[9],[23],{"type":18,"name":33,"description":20,"armGroupLabels":34,"otherNames":35},"Low-Dose Naltrexone, 6.0mg",[9],[23],[37],{"name":38,"affiliation":5,"role":39},"Jarred Younger, PhD","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","205-975-5821",null,"youngerlab@uab.edu",[47],{"facility":5,"status":44,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Birmingham","Alabama","35243","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-86.80249,33.52066,{"lat":57,"lon":56},[60,64],{"name":61,"role":42,"phone":62,"phoneExt":44,"email":63},"Catherine Burley","205-975-5907","psych-youngerlab@mail.ad.uab.edu",{"name":38,"role":39,"phone":44,"phoneExt":44,"email":44},{"type":39,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Jarred Younger","Professor",[69],{"name":70,"class":71},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100614890","phase-2-low-dose-naltrexone-for-mecfs-dose-finding-100614890",false,"NCT07285473","Low-Dose Naltrexone For ME\u002FCFS: Dose-Finding","Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS): Dose-Finding","Inclusion Criteria:\n\n* Between ages of 18 and 65\n* Living in Alabama\n* Meets ME-ICC criteria\n\nExclusion Criteria:\n\n* Abnormal hepatic function\n* Abnormal renal function\n* Abnormal complete blood count\n* Evidence of active or chronic systemic infection\n* A1C \\> 9.0%\n* Current opioid analgesic use\n* Pregnant or plans to become pregnant during the study participation period\n* Auto-immune disorder\n* Enrolled in other experimental treatment study","ALL","18 Years","65 Years",{"count":83,"type":84},75,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS). A remote trial approach is used, with eligibility open to the state of Alabama.",[90],"Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome",[90,92],"ME\u002FCFS","NOT_YET_RECRUITING","2026-08-19",{"date":96,"type":97},"2026-08-21","ACTUAL",{"date":99,"type":84},"2026-10-01",{"date":101,"type":84},"2028-04-01",{"name":5,"class":6},1]